In my opinion, I hope that Pali is not dead. Paired in the other ZIOP P2 trials and upcoming IL12 we have to wonder why these trials are ongoing and not stopped also. As we all hope, we will see something soon from Kirk, ZIOP & Intrexon about the way we are heading. Like I said IMO.
That is why we need zKirk or Lewis to clearly articulate whether or not Pali itself is the problem or the STS trial was simply poorly designed and/or run. The lack of reporting on PFS is still a head scratcher.
It really would be nice to hear from ZIOP management. The stock implodes, which happens, but to have management stay so tight-lipped is very perplexing. Pali was based on Ifosfamide. And Ifosfamide was a failed drug for STS due to toxicity and other side effects. In that Pali failed the trials clearly states to me that Pali is a dead end. Let's move on to newer and better non-legacy drugs. There's a reason there has been zero new drugs for STS in the last 30 years. IL-12 is based in part on the use of Palifosfamide. And Pali just failed a phase III trial. At this point, is Pali really worth the time and risk to have another failed clinical trial, albeit gene therapy this round?? What ZIOP has planned is a mystery and a secret to all of us who have lost our money up to this point. Obviously what I say here is IMO and I'm by no means an expert on the subject.
Come on ZIOP lets hear what you have planned!
My Long-Term Sentiment: Too confused to answer.